PMID- 29461610
OWN - NLM
STAT- MEDLINE
DCOM- 20191105
LR  - 20191105
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 22
IP  - 3
DP  - 2018 Feb
TI  - The effect of DC+CIK combined therapy on rat liver cancer model and its 
      modulatory effect on immune functions.
PG  - 778-785
LID - 14312 [pii]
LID - 10.26355/eurrev_201802_14312 [doi]
AB  - OBJECTIVE: Primary liver cancer is a sort of the most common solid tumors 
      occurred in the digestive system. The incidence and mortality rate maintain at a 
      high level, thus leading to heavy economic and psychological burdens for 
      patients. Next-generation biological therapy, such as cellular immune treatment, 
      improves the medicine efficacy. Cytokine-induced killer (CIK) cells can 
      effectively clear residual tumor lesion and inhibit metastasis or recurrence. 
      Dendritic cells (DCs) can specifically eliminate tumor cells via modulating 
      cellular immune function of the host. This study aimed to investigate the 
      function of DC+CIK combined treatment on rat liver model and its effect on immune 
      functions. MATERIALS AND METHODS: RH-35 tumor cell was used to prepare live 
      cancer model on Wistar rats, which were further divided into control, CIK and 
      DC+CIK groups, in which rats received autograft CIK and DCs. Tumor size was later 
      measured along with liver function index. The secretions of IFN-gamma, IL-4, and 
      TNF-alpha were measured by Real-time PCR and Western blotting. RESULTS: Both CIK and 
      DC+CIK treatment significantly reduced tumor size and improved liver function, 
      increased secretion of IFN-gamma, IL-4, and TNF-alpha, decreased Bcl-2 expression and 
      enhanced Bax expression (p < 0.05 compared to control group). DC+CIK combined 
      therapy presented significantly better efficacy than CIK did. CONCLUSIONS: DC+CIK 
      combined therapy can protect the host against tumors invasion via modulating body 
      immune or liver function, regulating apoptosis/anti-apoptosis balance, which 
      shows better efficacy than CIK alone, and can work as a novel biological 
      therapeutic strategy for liver cancer.
FAU - He, W
AU  - He W
AD  - Department of Interventional Radiology, the Affiliated Cancer Hospital of Guizhou 
      Medical University, Guiyang, China. hilltakeqwe@sina.com.
FAU - Huang, Z
AU  - Huang Z
FAU - Zhou, S
AU  - Zhou S
FAU - Huang, L
AU  - Huang L
FAU - Wang, B
AU  - Wang B
FAU - Zhu, L
AU  - Zhu L
FAU - Ding, Y
AU  - Ding Y
FAU - Yu, Y-L
AU  - Yu YL
FAU - Zhang, S
AU  - Zhang S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Animals
MH  - Apoptosis/immunology
MH  - Cell Line, Tumor
MH  - Cell- and Tissue-Based Therapy/*methods
MH  - Cytokine-Induced Killer Cells/*immunology/transplantation
MH  - Dendritic Cells/*immunology/transplantation
MH  - Immunotherapy/*methods
MH  - Liver Neoplasms/immunology/pathology/therapy
MH  - Liver Neoplasms, Experimental/*immunology/*therapy
MH  - Male
MH  - Neoplasm Recurrence, Local/immunology/therapy
MH  - Random Allocation
MH  - Rats
MH  - Rats, Wistar
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/immunology
EDAT- 2018/02/21 06:00
MHDA- 2019/11/07 06:00
CRDT- 2018/02/21 06:00
PHST- 2018/02/21 06:00 [entrez]
PHST- 2018/02/21 06:00 [pubmed]
PHST- 2019/11/07 06:00 [medline]
AID - 14312 [pii]
AID - 10.26355/eurrev_201802_14312 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2018 Feb;22(3):778-785. doi: 
      10.26355/eurrev_201802_14312.